Göksel Leblebisatan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Göksel Leblebisatan has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Hatice Ilgen Sasmaz
Cukurova Universitesi
4 shared publications - Adnan Barutçu
Cukurova University, Faculty of Medicine
3 shared publications - Ali Bay
Department of Pediatrics, Division of Pediatric Hematology, Gaziantep University, Gaziantep, Turkey
3 shared publications - Dincer Yildizdas
Division of Pediatric Critical Care, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Türkiye
3 shared publications Fatih Temiz
Adana Numune Research and Education Hospital
3 shared publicationsİlgen Şaşmaz
Department of Pediatric Hematology, Cukurova University Faculty of Medicine, Adana, Turkey
3 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in The Egyptian Journal of Otolaryngology
- Vol. 42 (1) , 250
Audiovestibular findings in beta-thalassemia patients receiving chelation therapy: an observational cross-sectional study
Background: Iron chelators, including deferasirox, deferiprone, and deferoxamine, are used to reduce iron overload in patients with beta thalassemia. Deferoxamine has the most consistently reported dose- and duration-related ototoxic profile, whereas evidence regarding cochlear or vestibular involvement with deferiprone and deferasirox remains limited. This study aimed to evaluate vestibular function in patients with beta thalassemia receiving chelation therapy using modern vestibular test batteries, including the video head impulse test and cervical vestibular evoked myogenic potentials. Methods: Forty patients with beta thalassemia receiving iron chelation therapy were included in the study. The patient group consisted of 17 females and 23 males, with a mean age of 18.7 ± 5.2 years. Patients were treated with deferasirox, deferiprone, deferoxamine, or combination regimens. Because deferasirox was the predominant chelator in the cohort, used in 33 of 40 patients, the findings should be interpreted primarily in relation to deferasirox exposure. The control group included 25 healthy individuals, consisting of 13 females and 12 males, with a mean age of 20.5 ± 5.7 years and no auditory or vestibular complaints. Auditory function was assessed using pure-tone audiometry and acoustic immittance measures, while vestibular function was evaluated using the video head impulse test and cervical vestibular evoked myogenic potentials. Results: There were no statistically significant differences between the chelation and control groups in pure-tone averages, vestibulo-ocular reflex gains of the semicircular canals on the video head impulse test, or cervical vestibular evoked myogenic potential parameters, including p1 and n1 latencies and threshold values. However, the incidence of high-frequency sensorineural hearing loss was numerically higher in the chelation group, but this difference did not reach statistical significance. Conclusion: In this predominantly deferasirox-treated beta thalassemia cohort, chelation therapy was not associated with measurable vestibular dysfunction based on the video head impulse test or cervical vestibular evoked myogenic potentials. However, the numerically higher incidence of high-frequency sensorineural hearing loss may warrant consideration in audiological follow-up during chelation therapy. Because the number of patients receiving deferoxamine- or deferiprone-based regimens was limited, these findings should not be generalized to all iron chelators without larger agent-specific studies.
- 25 September 2026
- Published by Springer Nature in The Egyptian Journal of Otolaryngology
- Vol. 42 (1) , 250
Open AccessAudiovestibular findings in beta-thalassemia patients receiving chelation therapy: an observational cross-sectional study
Background: Iron chelators, including deferasirox, deferiprone, and deferoxamine, are used to reduce iron overload in patients with beta thalassemia. Deferoxamine has the most consistently reported dose- and duration-related ototoxic profile, whereas evidence regarding cochlear or vestibular involvement with deferiprone and deferasirox remains limited. This study aimed to evaluate vestibular function in patients with beta thalassemia receiving chelation therapy using modern vestibular test batteries, including the video head impulse test and cervical vestibular evoked myogenic potentials. Methods: Forty patients with beta thalassemia receiving iron chelation therapy were included in the study. The patient group consisted of 17 females and 23 males, with a mean age of 18.7 ± 5.2 years. Patients were treated with deferasirox, deferiprone, deferoxamine, or combination regimens. Because deferasirox was the predominant chelator in the cohort, used in 33 of 40 patients, the findings should be interpreted primarily in relation to deferasirox exposure. The control group included 25 healthy individuals, consisting of 13 females and 12 males, with a mean age of 20.5 ± 5.7 years and no auditory or vestibular complaints. Auditory function was assessed using pure-tone audiometry and acoustic immittance measures, while vestibular function was evaluated using the video head impulse test and cervical vestibular evoked myogenic potentials. Results: There were no statistically significant differences between the chelation and control groups in pure-tone averages, vestibulo-ocular reflex gains of the semicircular canals on the video head impulse test, or cervical vestibular evoked myogenic potential parameters, including p1 and n1 latencies and threshold values. However, the incidence of high-frequency sensorineural hearing loss was numerically higher in the chelation group, but this difference did not reach statistical significance. Conclusion: In this predominantly deferasirox-treated beta thalassemia cohort, chelation therapy was not associated with measurable vestibular dysfunction based on the video head impulse test or cervical vestibular evoked myogenic potentials. However, the numerically higher incidence of high-frequency sensorineural hearing loss may warrant consideration in audiological follow-up during chelation therapy. Because the number of patients receiving deferoxamine- or deferiprone-based regimens was limited, these findings should not be generalized to all iron chelators without larger agent-specific studies.
- 12 August 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 187
Eltrombopag-associated remodeling of the MAIT, MR1+ and γδ T cells in pediatric immune thrombocytopenia
- 12 August 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 187
Eltrombopag-associated remodeling of the MAIT, MR1+ and γδ T cells in pediatric immune thrombocytopenia
- Open Access
- 21 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1818-1827
Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial
Summary: Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline characteristics and protocol‐defined dose adjustments on the achievement and sustainability of response. The cumulative percentage of patients who achieved a platelet response (2 consecutive platelet counts ≥50 × 10 9 /L) by days 15 and 22 was 70.4% and 75.9%, respectively, with avatrombopag (placebo, 0% at both days). Only minor differences were observed by baseline characteristics. Among the 92.6% of patients (50/54) treated with avatrombopag who achieved a clinically meaningful platelet response (platelet count ≥30 × 10 9 /L), the mean percentage of time with response was 62.5%. Protocol‐specified dose holds due to a platelet count >250 × 10 9 /L occurred for 61.1% of patients, which may have impacted the efficacy outcomes. 78.3% of non‐durable responders had ≥1 dose holds prompted by a platelet count of 250–400 × 10 9 /L, a platelet count that would not prompt a dose hold in real‐world clinical practice. Avatrombopag demonstrated a clinically meaningful platelet response across the clinical and demographic subgroups in this heavily pre‐treated and refractory paediatric ITP population.
- 21 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1818-1827
Open AccessAvatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial
Summary: Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline characteristics and protocol‐defined dose adjustments on the achievement and sustainability of response. The cumulative percentage of patients who achieved a platelet response (2 consecutive platelet counts ≥50 × 10 9 /L) by days 15 and 22 was 70.4% and 75.9%, respectively, with avatrombopag (placebo, 0% at both days). Only minor differences were observed by baseline characteristics. Among the 92.6% of patients (50/54) treated with avatrombopag who achieved a clinically meaningful platelet response (platelet count ≥30 × 10 9 /L), the mean percentage of time with response was 62.5%. Protocol‐specified dose holds due to a platelet count >250 × 10 9 /L occurred for 61.1% of patients, which may have impacted the efficacy outcomes. 78.3% of non‐durable responders had ≥1 dose holds prompted by a platelet count of 250–400 × 10 9 /L, a platelet count that would not prompt a dose hold in real‐world clinical practice. Avatrombopag demonstrated a clinically meaningful platelet response across the clinical and demographic subgroups in this heavily pre‐treated and refractory paediatric ITP population.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15562
Pediatric posterior reversible encephalopathy syndrome: Age related clinico‐radiological profile and neurologic outcomes
Background: The aim of this study was to analyze the characteristics of pediatric posterior reversible encephalopathy syndrome (PRES) to determine clinical and radiologic differences between younger and older age groups, and to identify risk factors for development of any neurologic sequelae.Methods: The study cohort consisted of confirmed pediatric PRES patients in a tertiary care university hospital from January, 2015, to December, 2020. Demographic and clinical properties, radiological manifestations, and neurologic outcomes were noted. Children aged ≤6 years were compared with those older than 6 years and factors affecting neurologic outcomes were evaluated.Results: The most common underlying diseases were oncological (37%) and kidney diseases (29%). Epileptic seizures were the most frequent symptoms at initial clinical presentation. The regions in the brain that were most commonly involved were the occipital region (n = 65, 96%), the parietal region (n = 52, 77%), and the frontal lobe (n = 35, 54%). Magnetic resonance imaging (MRI) findings were consistent with atypical patterns in most of the study cohort (71%). Patients with unfavorable clinical outcomes (n = 13, 19.1%) had longer initial seizure times and longer encephalopathy times, lower leucocyte and absolute neutrophil counts, and lower neutrophil to lymphocyte ratios. No relationship was found between MRI findings, involvement patterns, and neurologic outcomes.Conclusions: No clinically specific differences between two different age groups were found. Atypical imaging manifestations of pediatric PRES in our study had an incidence that was as high as those found in earlier adult studies. Multivariate logistic regression analysis showed that the initial neutrophil to lymphocyte ratio, absolute neutrophil counts, and white cell counts could not predict poor neurologic outcomes.
- 1 January 2023
- Published by Wiley in Pediatrics International
- Vol. 65 (1) , e15562
Pediatric posterior reversible encephalopathy syndrome: Age related clinico‐radiological profile and neurologic outcomes
Background: The aim of this study was to analyze the characteristics of pediatric posterior reversible encephalopathy syndrome (PRES) to determine clinical and radiologic differences between younger and older age groups, and to identify risk factors for development of any neurologic sequelae.Methods: The study cohort consisted of confirmed pediatric PRES patients in a tertiary care university hospital from January, 2015, to December, 2020. Demographic and clinical properties, radiological manifestations, and neurologic outcomes were noted. Children aged ≤6 years were compared with those older than 6 years and factors affecting neurologic outcomes were evaluated.Results: The most common underlying diseases were oncological (37%) and kidney diseases (29%). Epileptic seizures were the most frequent symptoms at initial clinical presentation. The regions in the brain that were most commonly involved were the occipital region (n = 65, 96%), the parietal region (n = 52, 77%), and the frontal lobe (n = 35, 54%). Magnetic resonance imaging (MRI) findings were consistent with atypical patterns in most of the study cohort (71%). Patients with unfavorable clinical outcomes (n = 13, 19.1%) had longer initial seizure times and longer encephalopathy times, lower leucocyte and absolute neutrophil counts, and lower neutrophil to lymphocyte ratios. No relationship was found between MRI findings, involvement patterns, and neurologic outcomes.Conclusions: No clinically specific differences between two different age groups were found. Atypical imaging manifestations of pediatric PRES in our study had an incidence that was as high as those found in earlier adult studies. Multivariate logistic regression analysis showed that the initial neutrophil to lymphocyte ratio, absolute neutrophil counts, and white cell counts could not predict poor neurologic outcomes.
- Open Access
- 30 June 2022
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 6 (6) , 640-642
Papillary thyroid cancer in a child with hemophilia A
Hemophilia A is a hereditary hemorrhagic disorder associated with bleeding episodes and characterized by deficiency or dysfunction of coagulation protein factor VIII. Cancer incidence was found to increase in hemophilic patients. A case of a 6-year old boy with papillary thyroid cancer and hemophilia who underwent a successful total thyroidectomy and bilateral modified radical lymph node dissection with appropriate peri-operative management consisting of Factor VIII replacement is presented.
- 30 June 2022
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 6 (6) , 640-642
Open AccessPapillary thyroid cancer in a child with hemophilia A
Hemophilia A is a hereditary hemorrhagic disorder associated with bleeding episodes and characterized by deficiency or dysfunction of coagulation protein factor VIII. Cancer incidence was found to increase in hemophilic patients. A case of a 6-year old boy with papillary thyroid cancer and hemophilia who underwent a successful total thyroidectomy and bilateral modified radical lymph node dissection with appropriate peri-operative management consisting of Factor VIII replacement is presented.
- 20 August 2021
- Published by Galenos Yayinevi in The Journal of Pediatric Research
- Vol. 8 (3) , 251-256
Evaluation of Children Receiving Tissue Plasminogen Activator Therapy for Thrombosis: Single Center Experience
- 20 August 2021
- Published by Galenos Yayinevi in The Journal of Pediatric Research
- Vol. 8 (3) , 251-256
Evaluation of Children Receiving Tissue Plasminogen Activator Therapy for Thrombosis: Single Center Experience
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1887-1893
Silent cerebral infarct in sickle cell anemia patients of southern Turkey
Background/aim: Silent cerebral infarct (SCI) is an ischemic lesion seen before clinical signs of brain infarct and ischemic changes in brain tissue. This study aimed to detect SCI with noninvasive methods and to determine related risk factors in patients with sickle cell anemia (SCA). Materials and methods: Fifty-four SCA patients who had no history of cerebral infarct and whose neurological examinations were normal were included in this study. Brain magnetic resonance imaging (MRI) and diffusion MRI were taken and the acquired data was compared statistically. Results: SCI was detected in 11.1% (6/54) of the patients. No statistical differences in age, sex, physical examination findings, or treatments were detected between the 2 groups (with and without SCI). When examined in terms of HbS, the median (min-max) value in SCI-positive patients was 85.4 (80.5-92.1); the median value was 77.2 (49.0-96.7) in SCI-negative patients. The HbS values of the SCI group were statistically significantly higher than those of the group without SCI (P = 0.014). Patients with the HbSS or HbS beta 0 genotypes had a significantly higher prevalence of SCI when compared with other sickle cell syndromes (P = 0.038). Conclusion: SCI is not uncommon among SCA patients in Turkey. The presence of homozygote HbSS/S beta 0 genotype, high MCV, and HbS are risk factors for SCI.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1887-1893
Open AccessSilent cerebral infarct in sickle cell anemia patients of southern Turkey
Background/aim: Silent cerebral infarct (SCI) is an ischemic lesion seen before clinical signs of brain infarct and ischemic changes in brain tissue. This study aimed to detect SCI with noninvasive methods and to determine related risk factors in patients with sickle cell anemia (SCA). Materials and methods: Fifty-four SCA patients who had no history of cerebral infarct and whose neurological examinations were normal were included in this study. Brain magnetic resonance imaging (MRI) and diffusion MRI were taken and the acquired data was compared statistically. Results: SCI was detected in 11.1% (6/54) of the patients. No statistical differences in age, sex, physical examination findings, or treatments were detected between the 2 groups (with and without SCI). When examined in terms of HbS, the median (min-max) value in SCI-positive patients was 85.4 (80.5-92.1); the median value was 77.2 (49.0-96.7) in SCI-negative patients. The HbS values of the SCI group were statistically significantly higher than those of the group without SCI (P = 0.014). Patients with the HbSS or HbS beta 0 genotypes had a significantly higher prevalence of SCI when compared with other sickle cell syndromes (P = 0.038). Conclusion: SCI is not uncommon among SCA patients in Turkey. The presence of homozygote HbSS/S beta 0 genotype, high MCV, and HbS are risk factors for SCI.
- Open Access
- 17 March 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
OUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
- 17 March 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (3) , 139-144
Open AccessOUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
- 30 September 2019
- Published by Cagdas Tip Dergisi: Journal of Contemporary Medicine in Journal of Contemporary Medicine
- Vol. 9 (3) , 197-202
Comparison Of Pro-BNP Levels And Myocardial Performance Index Before And After Iron Treatment In Children With Congenital Cyanotic Heart Disease With Iron Deficiency Anemia
Introduction: Our aim was to compare NT-proBNP levels and cardiac functions after iron therapy in children with congenital cyanotic heart disease who had iron deficiency anemia.Materials and Methods: We included 40 children with pre-established cyanotic congenital heart disease and accompanying iron deficiency anemia, between the age of 6 months and 17 years, who were admitted to the outpatient clinic of Çukurova University Faculty of Medicine, Department of Pediatric Cardiology between September 2015 and March 2016. We recorded demographic data and performed following investigations: complete blood count, peripheral blood smear, reticulocyte count, measurement of serum iron levels, total iron-binding capacity, ferritin levels, transferrin saturation and NT-proBNP levels, and echocardiographic examination.Results: There was a statistically significant increase in following laboratory parameters after iron therapy: hemoglobin, hematocrit, MCV, MCHC, serum iron and ferritin, transferrin saturation and oxygen saturation. During the follow-up period, RDW and NT-proBNP levels were significantly decreased. In left ventricular tissue doppler; there was a significant difference in MPI measurements before and after treatment. There was no significant difference in other echocardiography findings. Conclusion: Iron therapy has improved cardiac functions in children with cyanotic congenital heart disease, and NT-proBNP levels can be used to evaluate the efficacy of treatment in the follow-up period.
- 30 September 2019
- Published by Cagdas Tip Dergisi: Journal of Contemporary Medicine in Journal of Contemporary Medicine
- Vol. 9 (3) , 197-202
Comparison Of Pro-BNP Levels And Myocardial Performance Index Before And After Iron Treatment In Children With Congenital Cyanotic Heart Disease With Iron Deficiency Anemia
Introduction: Our aim was to compare NT-proBNP levels and cardiac functions after iron therapy in children with congenital cyanotic heart disease who had iron deficiency anemia.Materials and Methods: We included 40 children with pre-established cyanotic congenital heart disease and accompanying iron deficiency anemia, between the age of 6 months and 17 years, who were admitted to the outpatient clinic of Çukurova University Faculty of Medicine, Department of Pediatric Cardiology between September 2015 and March 2016. We recorded demographic data and performed following investigations: complete blood count, peripheral blood smear, reticulocyte count, measurement of serum iron levels, total iron-binding capacity, ferritin levels, transferrin saturation and NT-proBNP levels, and echocardiographic examination.Results: There was a statistically significant increase in following laboratory parameters after iron therapy: hemoglobin, hematocrit, MCV, MCHC, serum iron and ferritin, transferrin saturation and oxygen saturation. During the follow-up period, RDW and NT-proBNP levels were significantly decreased. In left ventricular tissue doppler; there was a significant difference in MPI measurements before and after treatment. There was no significant difference in other echocardiography findings. Conclusion: Iron therapy has improved cardiac functions in children with cyanotic congenital heart disease, and NT-proBNP levels can be used to evaluate the efficacy of treatment in the follow-up period.
- 18 August 2019
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 36 (6) , 376-381
A homozygote novel L451W mutation in CECR1 gene causes deficiency of adenosine deaminase 2 in a pediatric patient representing with chronic lymphoproliferation and cytopenia
Deficiency of Adenosine Deaminase 2 (DADA2) is a monogenic autoinflammatory disorder characterized by livedo reticularis, skin ulcers, subcutaneous rash, aphthous ulcers, and leukocytoclastic vasculitis, neurological signs such as early onset stroke and polyneuropathy. A minority of DADA2 patients suffer from severe cytopenia and lymphoproliferation. Herein, we report an adolescent patient, followed up as having a hematological disorder for many years, eventually diagnosed as having DADA2. In view of the presence of elevated acute phase reactants, hepatosplenomegaly, low IgM level, lymphopenia, anemia, and neutropenia, and a subtle neurological involvement we considered DADA2 diagnosis. The diagnosis was confirmed by identification of a novel L451W mutation in CECR1 gene. The patient has been successfully treated with etanercept, monthly intravenous immunoglobulin replacement, and low-dose methylprednisolone. In conclusion, although the absence of skin and neurological findings, low IgM levels, and persistent lymphopenia should lead the physicians to consider DADA2 in patients with particularly complicated hematological abnormalities.
- 18 August 2019
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 36 (6) , 376-381
A homozygote novel L451W mutation in CECR1 gene causes deficiency of adenosine deaminase 2 in a pediatric patient representing with chronic lymphoproliferation and cytopenia
Deficiency of Adenosine Deaminase 2 (DADA2) is a monogenic autoinflammatory disorder characterized by livedo reticularis, skin ulcers, subcutaneous rash, aphthous ulcers, and leukocytoclastic vasculitis, neurological signs such as early onset stroke and polyneuropathy. A minority of DADA2 patients suffer from severe cytopenia and lymphoproliferation. Herein, we report an adolescent patient, followed up as having a hematological disorder for many years, eventually diagnosed as having DADA2. In view of the presence of elevated acute phase reactants, hepatosplenomegaly, low IgM level, lymphopenia, anemia, and neutropenia, and a subtle neurological involvement we considered DADA2 diagnosis. The diagnosis was confirmed by identification of a novel L451W mutation in CECR1 gene. The patient has been successfully treated with etanercept, monthly intravenous immunoglobulin replacement, and low-dose methylprednisolone. In conclusion, although the absence of skin and neurological findings, low IgM levels, and persistent lymphopenia should lead the physicians to consider DADA2 in patients with particularly complicated hematological abnormalities.